No plan B?
08/12/18 -"We have taken Bayer’s most recent strategy update as well as the information provided at the Investors Day into account. Our impression is that management has fully underestimated the problems and ..."
Pages
78
Language
English
Published on
08/12/18
You may also be interested by these reports :
03/05/24
Genmab’s Q1 sales exceeded expectations, although profitability fell somewhat short. This robust performance was led by strong growth across all the ...
03/05/24
We have rolled forward our model to include a new forecast year (2026) which will also see continued healthy top-line growth and profitability ...
02/05/24
CureVac did not really tidy things up. The cost-cutting measures, as presented, are insufficient and do not meet our ideal scenario of a focused and ...
02/05/24
The Q1 results exceeded the street’s expectations, driven by the strong momentum for Novo’s diabetes and obesity offerings. While the management ...